Clinical Trial

A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non alcoholic Fatty Liver Disease (NAFLD) (MAESTRO NAFLD-1)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The primary goal of this study is to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.

Information

Principal Investigator Gregg Wendorff, MD
Co-PI
Sponsor
Type of Trial Prospective/Interventional